EG LIFE SCIENCES LLC
READING, MA

EG LIFE SCIENCES LLC, Reading

Greg Coir joined EG Life Sciences in August of 2015 in the role of Executive Vice President. Greg brings 25+ years of professional staffing and solutions experience in the Life Sciences and Healthcare space, and will be directly responsible for the continued growth and development of the company. Greg held multiple leadership roles within Randstad, most recently as President of Randstad Pharma. Greg is a graduate of Merrimack College’s School of Business Management and is based out of the corporate headquarters in Wakefield, MA. Jayne Gill is passionate about solving the human capital issues that stifle the development of pharmaceutical products and medical devices during the manufacturing and quality assurance process. She has spent the majority of her career working with Life Sciences companies, helping them deploy consulting teams that enable them to work with the FDA to return to full production capabilities. At EG Life Sciences Jayne is responsible for the planning, execution and overall success for Life Sciences Consulting Services. She has also served as the Regional Vice President for Validant Consulting and the Northeast Vice President for Harvey Nash. Alan Greathouse serves as principal consultant for EG Life Sciences. He has over 12 years of pharmaceutical experience focused on the cGMP manufacturing of parental drug products. During his time within pharmaceutical manufacturing he held various positions all with increasing responsibility and scope. In addition, he has extensive experience associated with the manufacturing process and design, specifically lyophilization. Alan excels at working with teams to identify, remediate and improve manufacturing processes. He is a graduate of Hiram college and holds a Bachelors of Arts in Business Management. EG Life Sciences is a professional consulting services firm that delivers flexible, scalable solutions for Pharmaceutical, Biotechnology, and Medical Device companies, including the resources they need to meet the unique challenges of FDA regulations. When partnering with EG Life Sciences, our clients receive highly skilled professionals who are rapidly deployable on a national scale. These experts hit the ground running – working to produce high-level results – that are strategically delivered on time and within budget. EG Life Sciences Consulting provides clients with the ability to increase workload while ensuring compliance & quality within a regulated environment. EG Life Sciences Consulting is growing fast and we have the connections you need to get the Life Sciences jobs you want. At EG Life Sciences, we are strong as individuals but even stronger when we combine resources and work together as a group. Collaboration results in innovation. We believe diversity in backgrounds, thoughts, and ideas foster innovation. EG Life Sciences encourages a work environment where creativity, debate and continuous improvement are valued. We strongly believe it's imperative to support the communities that the Life Sciences group serves. Our Community program is designed to provide both company and individual volunteer time, donations and fundraisers to help organizations in need throughout the US.

KEY FACTS ABOUT EG LIFE SCIENCES LLC

Company name
EG LIFE SCIENCES LLC
Status
Active
Filed Number
M15000003975
FEI Number
473139523
Date of Incorporation
May 20, 2015
Age - 9 years
Home State
DE
Company Type
Foreign Limited Liability

CONTACTS

Website
http://eglifesciences.com
Phones
(888) 925-6847

EG LIFE SCIENCES LLC NEAR ME

Principal Address
55 Walkers Brook Drive,
6th Floor,
Reading,
MA,
01867,
US

See Also

Officers and Directors

The EG LIFE SCIENCES LLC managed by the two persons from Boxford, Franklin on following positions: CEO,, CFO

David Mackeen

Position
CEO, Active
From
Boxford, MA, 01921

Douglas Nelson

Position
CFO Active
From
Franklin, MA, 02038





Registered Agent is COGENCY GLOBAL INC

Address
115 North Calhoun Street, Suite 4, Tallahassee, FL, 32301

Events

February 21, 2018
REINSTATEMENT
September 23, 2016
REVOKED FOR ANNUAL REPORT

Annual Reports

2023
April 12, 2023
2022
April 19, 2022